Title:Myositis Associated with the Anti-COVID-19 Covishield Vaccine
Volume: 19
Issue: 1
Author(s): Amal Miqdadi*, Nouhad Benmansour and Mohammed Herrag
Affiliation:
- Respiratory Medicine, Cheikh Khalifa International University Hospital, Mohammed VI University of Health Sciences, Casablanca, Morocco
Keywords:
Vaccine, AZD1222, AstraZeneca, myositis, inflammatory myopathies, complication.
Abstract:
Introduction: The SARS-CoV-2 made the world stop its activities, and the only chance
of returning to normal life is the vaccine. But like any vaccination, some complications have been
reported. We report the case of a patient who presented a myositis following the administration of
the Covishield* (AZD1222, ChAdOx1 nCoV-19, AstraZeneca) COVID-19 vaccine.
Case Report: 12 hours after his first dose, an 84-year-old patient presented to us reporting a decreased
muscle strength: the patient can move against gravity but not against resistance. The biological
assessment showed that CK was at 4,250 IU/L, myoglobin was at 144 microgram/L and aldolases at
16.9 U/L. The patient received high doses of corticosteroids.
Discussion: The development of vaccines and immunization programs reduced the morbidity and
mortality of several diseases. Other case reports suggested the possible association between myopathies
and the administration of the hepatitis B vaccine and H1N1 plus the seasonal trivalent influenza
and other vaccines. The exact mechanism is still unknown, but a presumable autoimmune phenomenon
is incriminated.
Conclusion: The main purpose of this case report is to raise awareness about the possible link between
the COVID-19 vaccination and polymyositis and the urge to take charge to avoid further
complications.
